TY - JOUR
T1 - Effects of inhibition of calcium and potassium currents in guinea-pig cardiac contraction
T2 - Comparison of β-caryophyllene oxide, eugenol, and nifedipine
AU - Sensch, O.
AU - Vierling, W.
AU - Brandt, W.
AU - Reiter, M.
PY - 2000
Y1 - 2000
N2 - 1. To investigate the effects of the clove oil constituents β-caryophyllene oxide and eugenol on the heart muscle, experiments were performed on isolated papillary muscles and on ventricular myocytes of the guinea-pig. The results were compared with those obtained with the dihydropyridine, nifedipine. 2. All three substances exerted negative inotropic effects in heart muscle although with different potencies and different influences on the time course of the contraction curve. 3. They all reduced rested-state contractions (RSCs) in the presence of isoprenaline which are thought to be due to the Ca2+ current (I(Ca)). 4. β-Caryophyllene oxide, eugenol and nifedipine inhibited the I(Ca) in single cells from the guinea-pig ventricle in a concentration-dependent, reversible way, but with different potencies. 5. In addition to the I(Ca)-inhibiting effect, β-caryophyllene oxide strongly inhibited and eugenol slightly inhibited the potassium current. 6. The action potential of papillary muscles at a 1 Hz contraction frequency was greatly shortened by nifedipine, slightly shortened by eugenol, but not changed by β-caryophyllene oxide. 7. The inhibition of the potassium current by β-caryophyllene oxide obviously prevents a shortening of the action potential due to the diminution of the I(Ca). Accordingly, the negative inotropic effect of β-caryophyllene oxide is closely related to the inhibition of I(Ca). In contrast, eugenol and nifedipine, which shorten the action potential, exert stronger negative inotropic effects than expected from their influence on I(Ca). 8. The results show that the negative inotropic effect of a calcium channel blocker can be attenuated by an additional inhibition of potassium channels.
AB - 1. To investigate the effects of the clove oil constituents β-caryophyllene oxide and eugenol on the heart muscle, experiments were performed on isolated papillary muscles and on ventricular myocytes of the guinea-pig. The results were compared with those obtained with the dihydropyridine, nifedipine. 2. All three substances exerted negative inotropic effects in heart muscle although with different potencies and different influences on the time course of the contraction curve. 3. They all reduced rested-state contractions (RSCs) in the presence of isoprenaline which are thought to be due to the Ca2+ current (I(Ca)). 4. β-Caryophyllene oxide, eugenol and nifedipine inhibited the I(Ca) in single cells from the guinea-pig ventricle in a concentration-dependent, reversible way, but with different potencies. 5. In addition to the I(Ca)-inhibiting effect, β-caryophyllene oxide strongly inhibited and eugenol slightly inhibited the potassium current. 6. The action potential of papillary muscles at a 1 Hz contraction frequency was greatly shortened by nifedipine, slightly shortened by eugenol, but not changed by β-caryophyllene oxide. 7. The inhibition of the potassium current by β-caryophyllene oxide obviously prevents a shortening of the action potential due to the diminution of the I(Ca). Accordingly, the negative inotropic effect of β-caryophyllene oxide is closely related to the inhibition of I(Ca). In contrast, eugenol and nifedipine, which shorten the action potential, exert stronger negative inotropic effects than expected from their influence on I(Ca). 8. The results show that the negative inotropic effect of a calcium channel blocker can be attenuated by an additional inhibition of potassium channels.
KW - Calcium inward current (I(Ca))
KW - Eugenol
KW - Heart muscle
KW - Negative inotropic effect
KW - Nifedipine
KW - Papillary muscle
KW - Potassium current
KW - Rested-state contraction (RSC)
KW - Ventricular myocardium
KW - β-Caryophyllene oxide
UR - http://www.scopus.com/inward/record.url?scp=0033680088&partnerID=8YFLogxK
U2 - 10.1038/sj.bjp.0703673
DO - 10.1038/sj.bjp.0703673
M3 - Article
AN - SCOPUS:0033680088
SN - 0007-1188
VL - 131
SP - 1089
EP - 1096
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 6
ER -